Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages

被引:230
作者
Bibby, MC [1 ]
机构
[1] Univ Bradford, Tom Connors Canc Res Ctr, Bradford BD7 1DP, W Yorkshire, England
关键词
orthotopic; experimental tumours; drug discovery;
D O I
10.1016/j.ejca.2003.11.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Considering the enormous effort that has taken place over the years to discover new chemotherapeutic drugs for treating the common cancers, the conventional murine and xenograft test systems used to test efficacy for drug development have identified only a limited number of useful agents that are active clinically at well tolerated doses. In recent years, considerable effort has been made to develop more clinically relevant models by the use of orthotopic transplantation of tumour material in rodents. It has been shown that it is now possible to transplant tumour material from a variety of tumour types into the appropriate anatomical site and often these tumours will metastasise in a similar manner and to similar locations as the same tumour type will in human cancer. As yet, although a body of literature has amassed on the technique itself and its implications for metastasis, there are relatively few laboratories using these test systems in drug development programmes. Nevertheless, given the expertise now being developed and some interesting observations being made on the role of the tumour site on response to therapeutic agents, it is likely that the use of orthotopic systems will strengthen our ability to select the most appropriate molecules for recommended use in clinical studies. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:852 / 857
页数:6
相关论文
共 49 条
  • [1] ATWELL GJ, 1989, ANTI-CANCER DRUG DES, V4, P161
  • [2] ANTI-TUMOR ACTIVITY OF TCNU IN A PANEL OF TRANSPLANTABLE MURINE COLON TUMORS
    BIBBY, MC
    DOUBLE, JA
    MORRIS, CM
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (08): : 1361 - 1364
  • [3] POTENTIATION OF EO9 ANTITUMOR-ACTIVITY BY HYDRALAZINE
    BIBBY, MC
    SLEIGH, NR
    LOADMAN, PM
    DOUBLE, JA
    [J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (07) : 1033 - 1035
  • [4] Making the most of rodent tumour systems in cancer drug discovery
    Bibby, MC
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (11-12) : 1633 - 1640
  • [5] BOYD MR, 1989, CANC PRINCIPLES PRAC, P1
  • [6] BROWN JM, 1987, RAD RES P 8 INT C RA, P419
  • [7] ABNORMAL RESPONSE OF TUMOR VASCULATURE TO VASOACTIVE DRUGS
    CHAN, RC
    BABBS, CF
    VETTER, RJ
    LAMAR, CH
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1984, 72 (01) : 145 - 150
  • [8] THE EFFECT OF HYDRALAZINE ON THE TUMOR-CYTOTOXICITY OF THE HYPOXIC CELL CYTOTOXIN RSU-1069 - EVIDENCE FOR THERAPEUTIC GAIN
    CHAPLIN, DJ
    ACKER, B
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (04): : 579 - 585
  • [9] Chishima T, 1997, CANCER RES, V57, P2042
  • [10] CORBETT TH, 1987, INVEST NEW DRUG, V5, P3